JP2018525367A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018525367A5 JP2018525367A5 JP2018504105A JP2018504105A JP2018525367A5 JP 2018525367 A5 JP2018525367 A5 JP 2018525367A5 JP 2018504105 A JP2018504105 A JP 2018504105A JP 2018504105 A JP2018504105 A JP 2018504105A JP 2018525367 A5 JP2018525367 A5 JP 2018525367A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- pharmaceutical composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562198384P | 2015-07-29 | 2015-07-29 | |
| US62/198,384 | 2015-07-29 | ||
| US201662352637P | 2016-06-21 | 2016-06-21 | |
| US62/352,637 | 2016-06-21 | ||
| PCT/IB2016/054487 WO2017017623A1 (en) | 2015-07-29 | 2016-07-27 | Combined use of anti pd-1 and anti m-csf antibodies in the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018525367A JP2018525367A (ja) | 2018-09-06 |
| JP2018525367A5 true JP2018525367A5 (https=) | 2019-09-05 |
| JP6840127B2 JP6840127B2 (ja) | 2021-03-10 |
Family
ID=56682136
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018504105A Expired - Fee Related JP6840127B2 (ja) | 2015-07-29 | 2016-07-27 | がんの治療における抗ｐｄ−１抗体および抗ｍ−ｃｓｆ抗体の併用 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US11001628B2 (https=) |
| EP (1) | EP3328425B1 (https=) |
| JP (1) | JP6840127B2 (https=) |
| KR (1) | KR20180034426A (https=) |
| CN (1) | CN108136003A (https=) |
| AU (1) | AU2016300208B2 (https=) |
| BR (1) | BR112018000212A2 (https=) |
| CA (1) | CA2991857A1 (https=) |
| CL (1) | CL2018000222A1 (https=) |
| IL (1) | IL256691A (https=) |
| JO (1) | JO3784B1 (https=) |
| MX (1) | MX2018001263A (https=) |
| PH (1) | PH12018500174A1 (https=) |
| RU (1) | RU2742494C2 (https=) |
| SA (1) | SA518390834B1 (https=) |
| TN (1) | TN2017000554A1 (https=) |
| TW (1) | TWI735456B (https=) |
| WO (1) | WO2017017623A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10570204B2 (en) | 2013-09-26 | 2020-02-25 | The Medical College Of Wisconsin, Inc. | Methods for treating hematologic cancers |
| SG10201900002QA (en) | 2014-01-24 | 2019-02-27 | Dana Farber Cancer Institue Inc | Antibody molecules to pd-1 and uses thereof |
| EP3099717B1 (en) | 2014-01-31 | 2019-03-27 | Novartis AG | Antibody molecules to tim-3 and uses thereof |
| US20150259420A1 (en) | 2014-03-14 | 2015-09-17 | Novartis Ag | Antibody molecules to lag-3 and uses thereof |
| ES2771926T3 (es) | 2014-09-13 | 2020-07-07 | Novartis Ag | Terapias de combinación |
| CN114591433A (zh) | 2015-07-13 | 2022-06-07 | 西托姆克斯治疗公司 | 抗pd-1抗体、可活化抗pd-1抗体及其使用方法 |
| DK3317301T3 (da) | 2015-07-29 | 2021-06-28 | Immutep Sas | Kombinationsterapier omfattende antistofmolekyler mod lag-3 |
| MA43260A (fr) | 2015-11-18 | 2018-09-26 | Merck Sharp & Dohme | Liants pd1 et/ou lag3 |
| AR112603A1 (es) * | 2017-07-10 | 2019-11-20 | Lilly Co Eli | Anticuerpos biespecíficos inhibidores de punto de control |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| US12174192B2 (en) | 2018-07-12 | 2024-12-24 | Corvus Pharmaceuticals, Inc. | Methods for detecting and treating cancers having adenosine pathway activation |
| EP3820522A4 (en) | 2018-07-12 | 2022-05-18 | Corvus Pharmaceuticals, Inc. | METHODS OF DETECTION AND THERAPY OF CANCER WITH ACTIVATION OF THE ADENOSIN SIGNALING PATHWAY |
| WO2020044252A1 (en) * | 2018-08-31 | 2020-03-05 | Novartis Ag | Dosage regimes for anti-m-csf antibodies and uses thereof |
| MX2021009562A (es) * | 2019-02-12 | 2021-09-08 | Novartis Ag | Combinacion farmaceutica que comprende tno155 y un inhibidor de pd-1. |
| AU2020281535A1 (en) | 2019-05-24 | 2022-01-27 | Merck Patent Gmbh | Combination therapies using CDK inhibitors |
| EP3983440A1 (en) * | 2019-06-13 | 2022-04-20 | CytomX Therapeutics, Inc. | Use of an activatable anti-pdl1 antibody and an anti-ctla-4 antibody in a neoadjuvant combination therapy for the treatment of cancer |
| EP3983439A1 (en) * | 2019-06-13 | 2022-04-20 | CytomX Therapeutics, Inc. | Use of an activatable anti-pdl1 antibody and an anti-ctla-4 antibody in a combination therapy for the treatment of cancer |
| WO2021226984A1 (zh) * | 2020-05-15 | 2021-11-18 | 三生国健药业（上海）股份有限公司 | 一种抗pd-1和pd-l1的四价双特异性抗体 |
| WO2022118197A1 (en) | 2020-12-02 | 2022-06-09 | Pfizer Inc. | Time to resolution of axitinib-related adverse events |
| WO2023057882A1 (en) | 2021-10-05 | 2023-04-13 | Pfizer Inc. | Combinations of azalactam compounds with a pd-1 axis binding antagonist for the treatment of cancer |
| WO2023079428A1 (en) | 2021-11-03 | 2023-05-11 | Pfizer Inc. | Combination therapies using tlr7/8 agonist |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1753912B (zh) | 2002-12-23 | 2011-11-02 | 惠氏公司 | 抗pd-1抗体及其用途 |
| DK2311873T3 (en) * | 2004-01-07 | 2018-11-26 | Novartis Vaccines & Diagnostics Inc | M-CSF-SPECIFIC MONOCLONAL ANTIBODY AND APPLICATIONS THEREOF |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| PT2061512T (pt) * | 2006-08-23 | 2020-01-14 | Yeda Res & Dev | Conjugados de péptidos com rgd e fotossensibilizantes de (bacterio)clorofila e as suas utilizações |
| CN101516375B (zh) * | 2006-09-15 | 2012-10-03 | 詹森药业有限公司 | 类别-i具体组织蛋白脱乙酰基酶抑制剂与蛋白酶体抑制剂的组合 |
| PT2242773T (pt) | 2008-02-11 | 2017-09-15 | Cure Tech Ltd | Anticorpos monoclonais para o tratamento de tumores |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| WO2010098788A2 (en) | 2008-08-25 | 2010-09-02 | Amplimmune, Inc. | Pd-i antagonists and methods for treating infectious disease |
| CN102203132A (zh) | 2008-08-25 | 2011-09-28 | 安普利穆尼股份有限公司 | Pd-1拮抗剂的组合物和使用方法 |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| AR097306A1 (es) | 2013-08-20 | 2016-03-02 | Merck Sharp & Dohme | Modulación de la inmunidad tumoral |
| CA2920113A1 (en) * | 2013-08-20 | 2015-02-26 | Merck Sharp & Dohme Corp. | Treating cancer with a combination of a pd-1 antagonist and dinaciclib |
| AR097584A1 (es) * | 2013-09-12 | 2016-03-23 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano |
| SG11201601763SA (en) * | 2013-09-20 | 2016-04-28 | Bristol Myers Squibb Co | Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors |
| SG10201900002QA (en) * | 2014-01-24 | 2019-02-27 | Dana Farber Cancer Institue Inc | Antibody molecules to pd-1 and uses thereof |
-
2016
- 2016-07-27 AU AU2016300208A patent/AU2016300208B2/en not_active Ceased
- 2016-07-27 CA CA2991857A patent/CA2991857A1/en not_active Abandoned
- 2016-07-27 JP JP2018504105A patent/JP6840127B2/ja not_active Expired - Fee Related
- 2016-07-27 MX MX2018001263A patent/MX2018001263A/es unknown
- 2016-07-27 TN TNP/2017/000554A patent/TN2017000554A1/en unknown
- 2016-07-27 RU RU2018106876A patent/RU2742494C2/ru active
- 2016-07-27 KR KR1020187002247A patent/KR20180034426A/ko not_active Ceased
- 2016-07-27 WO PCT/IB2016/054487 patent/WO2017017623A1/en not_active Ceased
- 2016-07-27 BR BR112018000212A patent/BR112018000212A2/pt not_active IP Right Cessation
- 2016-07-27 US US15/879,064 patent/US11001628B2/en not_active Expired - Fee Related
- 2016-07-27 EP EP16750495.0A patent/EP3328425B1/en active Active
- 2016-07-27 CN CN201680044470.5A patent/CN108136003A/zh active Pending
- 2016-07-28 JO JOP/2016/0162A patent/JO3784B1/ar active
- 2016-07-29 TW TW105124178A patent/TWI735456B/zh not_active IP Right Cessation
-
2018
- 2018-01-01 IL IL256691A patent/IL256691A/en unknown
- 2018-01-23 PH PH12018500174A patent/PH12018500174A1/en unknown
- 2018-01-26 CL CL2018000222A patent/CL2018000222A1/es unknown
- 2018-01-29 SA SA518390834A patent/SA518390834B1/ar unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018525367A5 (https=) | ||
| RU2018106876A (ru) | Новая комбинация для применения при лечении злокачественного новообразования | |
| IL288012B1 (en) | Antibody molecules against lag–3 and their use | |
| ZA202403388B (en) | Small molecules for treatement of cancer | |
| JP2019508013A5 (https=) | ||
| JP2018507220A5 (https=) | ||
| JP2016531150A5 (https=) | ||
| JP2018501197A5 (https=) | ||
| RU2018146886A (ru) | Пути терапевтического применения ингибитора c-raf | |
| JP2017529838A5 (https=) | ||
| PE20211767A1 (es) | Anticuerpos anti-hla-g, composiciones que comprenden anticuerpos anti-hla-g y metodos de uso de anticuerpos anti-hla-g | |
| RU2018105846A (ru) | Комбинация антагониста pd-1 с ингибитором egfr | |
| HRP20191034T1 (hr) | Pripravci koji sadrže anti-cd38 protutijela i lenalidomid | |
| RU2018123717A (ru) | Комбинированные лечения, их применения и способы | |
| PE20241623A1 (es) | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos | |
| JP2011046732A5 (https=) | ||
| EA201890805A1 (ru) | Биспецифические антитела против cd3*cd19 | |
| RU2016130056A (ru) | Способы лечения кожной инфекции путем введения антагониста il-4r | |
| EA200801580A1 (ru) | Новые производные пирониндола и способ их получения | |
| RU2017120358A (ru) | Анти-il-1-бета антитела и способы их применения | |
| JP2017534645A5 (https=) | ||
| JP2017506669A5 (ja) | 膠芽腫の治療に使用するための組成物及びその使用 | |
| MX2019007404A (es) | Moleculas de union a adam9 y metodos de uso de las mismas. | |
| JP2018529661A5 (https=) | ||
| RU2017120361A (ru) | Антитела к pdgf-b и способы их применения |